Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-21

Clinical Trial Update: Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. [Phase 3]

View source ↗

Summary

Phase 3 trial update for atogepant in patients with episodic migraine who failed previous oral prophylactics; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Atogepant (Atogepant)

Snippet

Sponsor: Allergan | Conditions: Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2023-09-21